| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/15/2006 | CN1241568C Compound paracetamol and chlorphenamine maleate slow releasing tablet and its preparation |
| 02/15/2006 | CN1241567C Synergistic analgestic combination of opioid analgsic and cyclooxygenase-2 |
| 02/15/2006 | CN1241566C Cilostazol solid dispersion and its method for preparing tablet |
| 02/15/2006 | CN1241565C Edaravone medicine composition and preparation thereof |
| 02/15/2006 | CN1241564C Medicine having antivirus action |
| 02/15/2006 | CN1241563C Application of Jigansan extract in preparation of medicine for treating angiocardiopathy |
| 02/15/2006 | CN1241562C Application of forsythin in the process for preparing adiposis treating oral medicine and healthy food |
| 02/15/2006 | CN1241561C Taxane injecta preparation |
| 02/15/2006 | CN1241560C Application of methylmercury compound in the treatment of encephalic malignant tumour as a anticancer new drug |
| 02/15/2006 | CN1241559C Chinese traditional medicine hypoglycemic agent and preparing process thereof |
| 02/15/2006 | CN1241558C Atenolol guttate pill and method for preparing the same |
| 02/15/2006 | CN1241557C Ambroxol guttate pill and method for preparing the same |
| 02/15/2006 | CN1241556C Emodin injection preparation and its preparation method |
| 02/15/2006 | CN1241555C Elemene fatty emulsion injection and preparing method thereof |
| 02/15/2006 | CN1241549C Amphoteric liposomes and the use thereof |
| 02/15/2006 | CN1241545C Pharmaceutical composition |
| 02/15/2006 | CN1241542C 乳化组合物 Emulsified composition |
| 02/15/2006 | CN1241538C Anti-microbial compositions comprising salt of transition metal chelator |
| 02/15/2006 | CN1241536C Humectant and cosmetics and external preparation containing the same |
| 02/15/2006 | CN1241534C Cosmetic skin care compositions containing cumic alcohol |
| 02/15/2006 | CN1241532C Complex room container preparation and method for manufacturing the same |
| 02/14/2006 | USRE38984 comprising the use of known antifungal agents such as the azoles or polyenes in combination with a pneumocandin derivative antifungal agent |
| 02/14/2006 | US6998503 crystallized as an anhydrous, stoichiometric 1.5 HCl salt; inhibiting or modulating nitric oxide synthesis |
| 02/14/2006 | US6998500 Halogen-substitited carboxyanilides have the androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor; useful as male contraceptives and hormone replacement therapy |
| 02/14/2006 | US6998494 Preparation of trans-fused 3,3a,8,12b-tetrahydro-2h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives |
| 02/14/2006 | US6998474 used for prevention and/or treatment of pathologies, dysfunctions, disorders or conditions affecting the nervous system |
| 02/14/2006 | US6998426 Oil in water emulsion |
| 02/14/2006 | US6998423 Sulfonyl-amino or carbonyl-amino derivatives; osteoporosis bone disorders; therapeutic drug or kits including anti-resorptive agents, anabolic agents; |
| 02/14/2006 | US6998422 Using pravastatin mixture with taurine, panthethine and inosiutol and hexanicotinate; anticholesterol agent, cardiovascular disorders |
| 02/14/2006 | US6998421 Maybe used to treat inflammation and certain inflammation related diseases. The group of related lipid molecules are capable of inhibiting certain enzyme systems including phospholipase A2, and cyclooxygenase-2. The group of related |
| 02/14/2006 | US6998420 Oxazolidinone compounds |
| 02/14/2006 | US6998418 Acellular biological material chemically treated with genipin |
| 02/14/2006 | US6998417 Procyanidins as antineoplastic agents; topolisomerase, cylooxygenase, and/or lipoxygenase inhibitors; nitric oxide synthase modulators; hypotensive agents |
| 02/14/2006 | US6998416 Cyclic AMP-specific phosphodiesterase inhibitors |
| 02/14/2006 | US6998415 Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| 02/14/2006 | US6998414 Substituted arylamides as IP antagonists |
| 02/14/2006 | US6998413 Anticarcinogenica agents, antitumor agents; a new pyrrolo[1,2-a]benzimidazole derivatives from existing drug; cytotoxic; central nervous system, ovarian, and lung cancers; potentiation |
| 02/14/2006 | US6998412 Heterocyclic compounds |
| 02/14/2006 | US6998411 2-Methylheptylisonicotinate and process for production thereof |
| 02/14/2006 | US6998410 Treatment of Infant Respiratory Distress Syndrome or Adult Respiratory Distress Syndrome by administering a combination of a phospholipid lung surfactant with N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide |
| 02/14/2006 | US6998409 Drugs for treating chronic pain; stereoisomers; chemical synthesis from intermediates; nontoxic |
| 02/14/2006 | US6998408 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
| 02/14/2006 | US6998407 For prophylaxis and therapy of chronic or acute inflammatory or autoimmune diseases, those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease |
| 02/14/2006 | US6998406 Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments |
| 02/14/2006 | US6998405 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use |
| 02/14/2006 | US6998404 Adenosine receptor antagonists, especially aminophyllline; can also be used to help sustain a kidney for transplant purposes. |
| 02/14/2006 | US6998403 Antidepressants; N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-1,2-dihydro-3H-benzo[e]indole-3-carboxamide; antagonist of adrenergic receptor, serotonin receptor; anxiety, schizophrenia, Parkinson's disease, cognitive disorders, schizophrenia |
| 02/14/2006 | US6998402 7-(1-Acetylpentyl)-5-methyl-2-(4-methylbenzyl)imidazo[5,1-f][1,2,4]triazin-4(3H)-one; learning enhancement, concentration power, learning power, memory power; enzyme inhibitors of phosphodiesterase isoenzyme |
| 02/14/2006 | US6998401 Such as 2-(4-amino-2,3,5-trimethylphenoxy)-N-methyl-N-(4-piperidinyl)acetamide which has neuroprotective effects by inducing calcium binding proteins |
| 02/14/2006 | US6998400 Pharmaceutically active morpholinol |
| 02/14/2006 | US6998399 cognition activators; prevention of nicotinic receptors dysfunction, central nervous system; Alzheimer's disease, Parkinson's disease, Huntington's chorea, neurodegenerative diseases |
| 02/14/2006 | US6998397 administering medicament or food supplement containing 24-epibrassinolide to mammal in a daily dose of 0.03 200 micrograms per kilogram of body weight; for decreasing cholesterol, low-density lipoprotein and triglyceride levels in blood |
| 02/14/2006 | US6998396 measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator such as deferiprone; method can include measuring total urinary protein content, blood urea nitrogen, or creatinine |
| 02/14/2006 | US6998395 Controlled release formulation for preventing or treating risk factors for cardiovascular disease |
| 02/14/2006 | US6998394 Process for isolating physalins from plants and pharmaceutical compositions containing physalins |
| 02/14/2006 | US6998392 Formulation to treat or prevent parasitic infection |
| 02/14/2006 | US6998391 Method for treating diseases associated with abnormal kinase activity |
| 02/14/2006 | US6998390 Oxolide antibacterials |
| 02/14/2006 | US6998384 Surfactant prevention of lung complications from cancer chemotherapy |
| 02/14/2006 | US6998263 Methods of preparing and using a viral vector library |
| 02/14/2006 | US6998262 Polysaccharide extract of Dioscorea sp. and an orally active pharmaceutical composition comprising the same |
| 02/14/2006 | US6998244 contacting a cell transformed or transfected with an expression vector capable of expressing 5-HT4 receptor with a compound in presence of a ligand, monitoring CAMP formation in the cell, a change indicates compund as an antagonist or agonist |
| 02/14/2006 | US6998231 Coding or classification of prion sample; obtain sample, monitor physical properties of sample, compare to control |
| 02/14/2006 | US6998158 Multilayer electrometric material containing active chemical substance, and uses thereof |
| 02/14/2006 | US6998144 2,4-dihydroxybenzoic acid and sucralose in a weight ratio of .01-100% |
| 02/14/2006 | US6998138 Benzoic or cinnamoyl ester penetration enhancing agent |
| 02/14/2006 | US6998137 Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
| 02/14/2006 | US6998130 Compositions for the treatment of pigmentation disorders and methods for their manufacture |
| 02/14/2006 | US6998129 Comprises association between elastase inhibitor compound of the N-acylaminoamide family and at least one antiinflammatory compound; for improving skin ageing and/or photoageing signs by slowing down connective tissue alterations |
| 02/14/2006 | US6998123 interleukins (IL-11); fibronectins; glycoproteins |
| 02/14/2006 | US6998115 Biodegradable and biocompatible and may be used in a variety of drug delivery systems; suited for the delivery of polynucleotides |
| 02/14/2006 | US6998112 Sleep inducing toothpaste made with natural herbs and a natural hormone |
| 02/14/2006 | US6998110 High speed absorption; mixture of aqueous polar solvent, propellant, active material and flavor |
| 02/14/2006 | US6998109 Emu-based formulations with lidocaine for wound treatment by inhibiting microbial activity |
| 02/14/2006 | US6997909 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 02/14/2006 | CA2450740C Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 02/14/2006 | CA2375385C Propargyl phenyl ether a2a receptor agonists |
| 02/14/2006 | CA2374643C 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives as substance p antagonists |
| 02/14/2006 | CA2363145C Oxamic acids and derivatives as thyroid receptor ligands |
| 02/14/2006 | CA2338684C Injectable propofol formulations |
| 02/14/2006 | CA2336597C Hepatitis c inhibitor peptides |
| 02/14/2006 | CA2324493C Controlled release oral tablet having a unitary core |
| 02/14/2006 | CA2292586C Solid pharmaceutical dosage forms in form of a particulate dispersion |
| 02/14/2006 | CA2288793C Poly(vinyl alcohol) cryogel |
| 02/14/2006 | CA2269072C Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
| 02/14/2006 | CA2263167C Ether muscarinic antagonists |
| 02/14/2006 | CA2250863C Acridone-derived compounds useful as antineoplastic and antiretroviral agents |
| 02/14/2006 | CA2245197C Unsaturated derivatives in position -4 of 6-tert-butyl-1, 1-dimethylindan and their use in human or veterinary medicine and in cosmetics |
| 02/14/2006 | CA2241186C Benzimidazole derivatives |
| 02/14/2006 | CA2241094C Tri-substituted phenyl derivatives useful as pde iv inhibitors |
| 02/14/2006 | CA2241093C Tri-substituted phenyl derivatives useful as pde iv inhibitors |
| 02/14/2006 | CA2223014C Controlled release formulation having a preformed passageway |
| 02/14/2006 | CA2218945C 4-aminoquinazoline derivatives |
| 02/14/2006 | CA2210044C 4-hydroxy-piperidine derivatives |
| 02/14/2006 | CA2209825C Heterocyclic-fused pyridines |
| 02/14/2006 | CA2199400C Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases |
| 02/14/2006 | CA2192645C Tri-substituted phenyl derivatives useful as pde iv inhibitors |
| 02/14/2006 | CA2192644C Tri-substituted phenyl derivatives useful as pde iv inhibitors |
| 02/14/2006 | CA2192643C Tri-substituted phenyl derivatives useful as pde iv inhibitors |
| 02/14/2006 | CA2190148C Oral liquid alendronate formulations |